241 related articles for article (PubMed ID: 33802509)
1. Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study.
Adjei AA; Lopez CL; Schaid DJ; Sloan JA; Le-Rademacher JG; Loprinzi CL; Norman AD; Olson JE; Couch FJ; Beutler AS; Vachon CM; Ruddy KJ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802509
[TBL] [Abstract][Full Text] [Related]
2. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
[TBL] [Abstract][Full Text] [Related]
4. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance).
Boora GK; Kulkarni AA; Kanwar R; Beyerlein P; Qin R; Banck MS; Ruddy KJ; Pleticha J; Lynch CA; Behrens RJ; Züchner S; Loprinzi CL; Beutler AS
J Neurol Sci; 2015 Oct; 357(1-2):35-40. PubMed ID: 26143528
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
8. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
9. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
[TBL] [Abstract][Full Text] [Related]
10. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
[TBL] [Abstract][Full Text] [Related]
11. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
Smith EML; Zanville N; Kanzawa-Lee G; Donohoe C; Bridges C; Loprinzi C; Le-Rademacher J; Yang JJ
Support Care Cancer; 2019 Jul; 27(7):2599-2608. PubMed ID: 30460399
[TBL] [Abstract][Full Text] [Related]
12. Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes.
Le-Rademacher JG; Lopez CL; Kanwar R; Major-Elechi B; Abyzov A; Banck MS; Therneau TM; Sloan JA; Loprinzi CL; Beutler AS
J Neurol Sci; 2020 Apr; 411():116687. PubMed ID: 32018185
[TBL] [Abstract][Full Text] [Related]
13. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
14. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
15. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo.
Myftiu B; Hundozi Z; Sermaxhaj F; Blyta A; Shala N; Jashari F; Qorraj Bytyqi H; Hyseni E; Kurtishi I
Med Sci Monit; 2022 Aug; 28():e937856. PubMed ID: 36042691
[TBL] [Abstract][Full Text] [Related]
17. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.
Salgado TM; Liu J; Reed HL; Quinn CS; Syverson JG; Le-Rademacher J; Lopez CL; Beutler AS; Loprinzi CL; Vangipuram K; Smith EML; Henry NL; Farris KB; Hertz DL
Breast; 2020 Jun; 51():21-28. PubMed ID: 32193049
[TBL] [Abstract][Full Text] [Related]
18. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
[TBL] [Abstract][Full Text] [Related]
19. Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
Chen CS; Smith EML; Stringer KA; Henry NL; Hertz DL
Breast Cancer Res Treat; 2022 Aug; 194(3):551-560. PubMed ID: 35760975
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-induced neuropathy and colo-rectal cancer patient's quality of life: Practical lessons from a prospective cross-sectional, real-world study.
Prutianu I; Alexa-Stratulat T; Cristea EO; Nicolau A; Moisuc DC; Covrig AA; Ivanov K; Croitoru AE; Miron MI; Dinu MI; Ivanov AV; Marinca MV; Radu I; Gafton B
World J Clin Cases; 2022 Apr; 10(10):3101-3112. PubMed ID: 35647128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
